HMH Hospitals Corporation

HMH Hospitals Corporation, doing business as Hackensack University Medical Center, is a New Jersey-based non-profit healthcare organization that acts as a prime recipient of federal research grants and a prime contractor for specialized medical services, with 57% of recent awards held as prime and 43% as sub-recipient or subcontractor. The organization competes predominantly full-and-open, with no set-aside designations across its federal footprint.

HMH's capability portfolio centers on biomedical research and medical services. On the research side, the organization is a prolific recipient of federal grant funding for investigator-initiated and cooperative research spanning cancer biology, infectious disease, antimicrobial resistance, immunotherapy, vaccine development, and clinical trials. Representative grant work includes a $7.56 million Cooperative Agreement from the National Institute of Allergy and Infectious Diseases (CFDA 93.855) awarded June 20, 2025, to establish the Center for Accelerated Development of Drug Candidates Targeting High Threat Bacterial Infections, a public-private partnership with academic and pharmaceutical collaborators addressing drug-resistant pathogens; a $4.36 million Project Grant from the Defense Health Agency (CFDA 12.420) awarded September 30, 2025, to evaluate teletherapy efficacy for service members with traumatic brain injury; and a $995 thousand Project Grant from the Substance Abuse and Mental Health Services Administration (CFDA 93.490) awarded September 30, 2026, to expand SBIRT (Screening, Brief Intervention and Referral to Treatment) services for youth in New Jersey. On the contract side, HMH holds a single-award Indefinite Delivery Contract with the Veterans Integrated Service Network 2 (ceiling $360 thousand, awarded September 30, 2022, running through September 29, 2027) for animal services including research animal husbandry, cage services, and technical support for VA medical research programs. The organization also holds a multiple-award IDIQ for in vitro assessment of antimicrobial activity (IVAAA), awarded September 30, 2026, with a ceiling of $2,500 and completion date of September 29, 2036.

Customer concentration is heavily dominated by the National Institutes of Health (NIH). The National Institute of Allergy and Infectious Diseases (NIAID) anchors 49 awards across the recent portfolio, and the National Cancer Institute (NCI) carries 42 awards; these two NIH institutes alone represent the majority of HMH's federal work. The Department of Veterans Affairs Veterans Integrated Service Network 2 represents 9 awards with $682 thousand combined potential value, constituting nearly all of the organization's contract (rather than grant) work. The Health Resources and Services Administration (HRSA) carries 19 to 30 awards depending on subcategory designation. Ninety-five percent of the top-customer concentration is driven by HHS agencies, with NIH representing the dominant customer by far.

HMH's grant footprint is substantial and highly specialized. The organization acts as a prime recipient on approximately 60 NIH grants spanning cancer research (melanoma biomarkers, colorectal cancer mechanisms, breast cancer immunotherapy, multiple myeloma), infectious disease and antimicrobial resistance (tuberculosis drug optimization, Candida and Klebsiella resistance mechanisms, antiviral drug development), immunology (T-cell exhaustion, CAR-T cell therapy, graft-versus-host disease), and clinical outcomes research (lung cancer screening, asthma management, brain injury). The organization also receives grants from the Defense Health Agency for military health research, SAMHSA for substance abuse treatment and mental health services, NIST for sequencing facility infrastructure, the Department of Justice for violence intervention programs, and various HHS programs for dental care reimbursement and special pathogen treatment. As a sub-recipient, HMH participates in major research consortia led by Johns Hopkins University, Rutgers University, Columbia University, Duke University, Georgetown University, and others, typically performing specialized assays (fungal infection models, bacterial resistance testing, pharmacokinetic analysis), cohort recruitment and follow-up (ECHO pediatric environmental health, kidney transplant outcomes, trauma rehabilitation), or providing clinical site leadership for multisite trials.

Activity has grown substantially. Awards per year increased from 14 in 2022 to a peak of 49 in 2024, then moderated to 38 in 2025 and 25 so far in 2026; the source covers through October 5, 2026. Sixteen awards (combined potential value $17 thousand) reach ultimate completion within the next twenty-four months, representing modest recompete exposure. The organization's disclosed dollar obligated ($716.9 million) substantially exceeds combined potential value ($684 thousand), reflecting the fact that the source captures a narrow recent slice of a mature, long-standing research enterprise with large multi-year grants obligated over their full performance periods.

HMH's award structure reveals a hybrid model: the majority of funding flows through NIH and HHS grant mechanisms (investigator-initiated research, cooperative agreements, and project grants), while a small but strategically important contract footprint with the VA and emerging IDIQ vehicle provide fee-for-service medical research support. The organization operates as a sub-recipient in many large NIH cooperative agreements and research networks, anchoring specialized research capabilities (infectious disease diagnostics, oncology biomarkers, translational immunotherapy) within a broader hospital and research enterprise. Named corporate subsidiaries include Hackensack Meridian School of Medicine (private non-profit university) and Meridian Hospitals Corporation (non-profit hospital operator), indicating vertical integration of medical education and clinical care alongside research.